Kalyagen™ Announces Launch of Clinical Trial to Evaluate STEMREGEN® and Stem Cells for Advanced Heart Failure Patients

AUSTIN, Texas, Feb. 5, 2021 (SEND2PRESS NEWSWIRE) — Kalyagen™, along with the Sociedad Espanola de Medicina Regenerativa y Terapia Celular (the “Spanish Society of Regenerative Medicine and Cell Therapy”), is pleased to announce the launch of a multicenter clinical trial, “The Effect of Stemregen and Adipose Stroma Vascular Fraction (SVF) Either Individually or in Combination in Patient With Heart Failure,” to evaluate the use of stem cell therapies in patients suffering from heart failure. – News from Kalyagen, issued by Send2Press Newswire

Source